Trillium Strengthens its Board of Directors

Toronto, November 5 (ots/PRNewswire) - Trillium Therapeutics Inc., a
privately held biopharmaceutical company, announced today that
industry veterans Dr. Michael Berendt and Dr. John Dietrich have
joined its Board as independent directors. Trillium Chairman Dr.
Michael Moore commented: "It is a great pleasure to welcome these two
experienced biotech executives to the Board where they will enhance
our capabilities in strategic planning and product development. Their
appointments are commensurate with completion of an internal
financing round of CDN$12 million and the entry into clinical
development of Trillium's lead product, TTI-1612."

About Dr. Michael Berendt: Dr. Berendt is the President and CEO
of Aegera Therapeutics. Prior to joining Aegera, he served as
managing director of Research Corporation Technologies (RCT), a
US-based technology investment and management company, and AEA
Investors Inc., where focusing on growth equity investments in life
sciences companies. Previously Dr. Berendt was Senior Vice President
of Research for the Pharmaceutical Division of Bayer Corporation. He
is currently a director of Waters Corporation and has served on the
board of directors of numerous other life sciences companies. Dr.
Berendt received a doctoral degree in medical microbiology and
immunology from Hahnemann University.

About Dr. John Dietrich: Dr. Dietrich joined Ventrus Biosciences
in April 2007, where he currently serves as Vice President, Clinical
Operations. From 2000 to 2007, Dr. Dietrich was Vice President of
Research and Development at VIVUS, Inc, prior to which he was Vice
President of Research and Development at Cellegy Pharmaceuticals. Dr.
Dietrich served as Senior Vice President of Research and Development
at Allelix Biopharmaceuticals between 1991 and 1999. In this
position, he was responsible for all aspects of drug discovery and
development. Before joining Allelix, he held management positions at
Chemex and Revlon Health Care. Dr. Dietrich received his PhD in
pharmacology from the University of North Carolina at Chapel Hill.

About Trillium: Trillium Therapeutics Inc. is a private
biopharmaceutical company specializing in innovative therapies of
immune-mediated conditions, such as autoimmune and inflammatory
disorders, as well as cancer. The company's lead program, a
recombinant heparin-binding epidermal growth factor-like growth
factor (HB-EGF), is being developed for the prevention of necrotizing
enterocolitis and the treatment of interstitial cystitis. IND filing
on the lead product, TTI-1612, was submitted to the FDA in October
2008. In addition, Trillium has two preclinical programs targeting
the CD200 immunoregulatory axis; a CD200-specific monoclonal antibody
for the treatment of cancer, and a CD200Fc fusion protein for the
treatment of autoimmune and inflammatory diseases. The company has a
broad network of external academic and industry R&D collaborations,
including several license agreements with major US biotechnology
companies. To date the Company has raised approximately CDN$25
million in investment capital through Vengrowth Private Equity
Partners, Canadian Medical Discoveries Fund (CMDF) and BDC Venture
Capital.

For further information: Niclas Stiernholm, Ph.D., Chief
Executive Officer, Trillium Therapeutics Inc., 96 Skyway Avenue
Toronto, Ontario, M9W 4Y9, Canada, Tel: +1-416-595-0627, Fax:
+1-416-595-5835, niclas@trilliumtherapeutics.com,
http://www.trilliumtherapeutics.com/

ots Originaltext: Trillium Therapeutics Inc.
Im Internet recherchierbar: http://www.presseportal.de

Contact:
For further information: Niclas Stiernholm, Ph.D., Chief Executive
Officer, Trillium Therapeutics Inc., 96 Skyway Avenue Toronto,
Ontario, M9W 4Y9, Canada, Tel: +1-416-595-0627, Fax: +1-416-595-5835,
niclas@trilliumtherapeutics.com